Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 19/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 17/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1602494 | 0.89 | OPRD1 (0.79) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4927674 | 0.84 | OPRD1 (1.00) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5432433 | 0.83 | OPRD1 (0.71) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4924161 | 0.83 | OPRD1 (1.00) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4922241 | 0.83 | OPRD1 (0.70) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4929285 | 0.82 | OPRD1 (0.79) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4928931 | 0.82 | OPRD1 (0.72) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL4929198 | 0.82 | OPRD1 (1.00) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL12730803 | 0.82 | OPRD1 (0.72) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Hydrochloric Acid SCHEMBL29874927 | 0.82 | OPRD1 (0.97) | OPRD1OPRM1OPRK1KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176903-A1 | Novel Compounds with Analgesic Effect | ASTRAZENECA CANADA INC. (CA) | 2008-07-24 | — | — | US | disclosed |
| US-7312336-B2 | Compounds with analgesic effect | ASTRAZENECA CANADA INC. (CA) | 2007-12-25 | — | — | US | disclosed |
| EP-0946511-B1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040171612-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2004-09-02 | — | — | US | disclosed |
| US-6693117-B2 | PIPERIDIN-4-YLIDENE DERIVATIVES | ASTRAZENECA CANADA INC. (CA) | 2004-02-17 | — | — | US | disclosed |
| US-20030149023-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2003-08-07 | — | — | US | disclosed |
| US-6455545-B2 | GASTROINTESTINAL DISORDERS | ASTRAZENECA CANADA INC. (CA) | 2002-09-24 | — | — | US | disclosed |
| US-20010021715-A1 | Novel compounds with analgesic effect | ASTRA PHARMA INC. | 2001-09-13 | — | — | US | disclosed |
| US-6187792-B1 | PIPERIDIN-4-METHYLIDENE-4-BENZAMIDE DERIVATIVES; OPOID RECEPTOR ANTAGONISTS; CANCER PAIN | ASTRA PHARMA INC. (CA) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021715-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | OPRD1 4/4885OPRM1 3/4885OPRK1 2/4885 |
| US-20030149023-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | OPRD1 4/4885OPRM1 3/4885OPRK1 2/4885 |
| US-20080176903-A1 | Novel Compounds with Analgesic Effect | OPRL1, OPRK1, OPRM1 | OPRD1 4/4885OPRM1 3/4885OPRK1 2/4885 |
| US-20040171612-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | OPRD1 4/4885OPRM1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.